Touch Ativitavas

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +15

Neoadjuvant Osimertinib for Resectable <i>EGFR</i> -Mutated Non–Small Cell Lung Cancer

Jianxing He, Masahiro Tsuboi, Walter Weder et al. · Journal of Clinical Oncology · 2025 · 61 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Impact of CYP2D6 Polymorphisms on Tamoxifen Responses of Women with Breast Cancer: A Microarray-based Study in Thailand

Chonlaphat Sukasem, Ekaphop Sirachainan, Khunthong Pechatanan et al. · Asian Pacific Journal of Cancer Prevention · 2012 · 38 citations · Full text

Medicine, Genetics, Oncology +15

CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients

Chonlaphat Sukasem, Ekaphop Sirachainan, Sureerat Jaruhathai et al. · Pharmacogenomics and Personalized Medicine · 2012 · 32 citations · Full text

Life Sciences, Genetics, Oncology +13

Phase II, multi-center, open-label, single-arm clinical trial evaluating the efficacy and safety of Mycophenolate Mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): rationale and design of the ESMMO trial

Nut Koonrungsesomboon, Nuttapong Ngamphaiboon, Natavudh Townamchai et al. · BMC Cancer · 2020 · 18 citations · Full text

Medicine, Oncology, Pharmacology +13